Related Experiment Video
Updated: Feb 4, 2026

Perspectives on Neuroscience
Published on: July 31, 2007
HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment
Iraldo Bello-Rivero1, Yanelda Garcia-Vega2, Yaquelin Duncan-Roberts3
1Clinical Research Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Abstract:
The rational combination of recombinant IFN-α2b and IFN-γ resulted in a new formulation of interferons (HeberFERON) with improved pharmacodynamics. In basal cell carcinomas HeberFERON produces a more rapid antitumor effect and results in a larger number of complete responses. In patients with glioblastoma multiforme, the administration of HeberFERON after surgery and radiotherapy results in an estimated overall survival of 19 months. Patients with stage III or IV renal cell carcinoma also appear to benefit from the intravenous administration of HeberFERON, with prolongation of survival and good quality of live. HeberFERON offers a promising alternative formulation of interferons for the treatment of cancer with a very favorable safety profile.
Related Concept Videos
Treatment Resistant Cancers
Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Measurement of Bioavailability: Pharmacodynamic Methods
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Pharmacodynamics in Geriatric Patients: Effects of Age
Criticisms of the Evolutionary Perspective
Evolutionary psychology provides one explanation for these findings, suggesting...

